Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity

[Background]; Pancreatic ductal adenocarcinoma (PDAC) is a profoundly aggressive and fatal cancer. One of the key factors defining its aggressiveness and resilience against chemotherapy is the existence of cancer stem cells (CSCs). The important task of discovering upstream regulators of stemness th...

ver descrição completa

Detalhes bibliográficos
Autores: Zheng, Quan, Tang, Jiajia, Aicher, Alexandra, Bou Kheir, Tony, Sabanovic, Berina, Ananthanarayanan, Preeta, Reina, Chiara, Chen, Minchun, Gu, Jian-Min, He, Bin, Alcalá, Sonia, Behrens, Diana, Lawlor, Rita T., Scarpa, Aldo, Hidalgo, Manuel, Sainz, Bruno Jr., Sancho, Patricia, Heeschen, Christopher
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/349714
Acesso em linha:http://hdl.handle.net/10261/349714
Access Level:acceso abierto
Palavra-chave:Pancreatic ductal adenocarcinoma
Cancer stem cells
Metabolism
SOX2
MYC
Descrição
Resumo:[Background]; Pancreatic ductal adenocarcinoma (PDAC) is a profoundly aggressive and fatal cancer. One of the key factors defining its aggressiveness and resilience against chemotherapy is the existence of cancer stem cells (CSCs). The important task of discovering upstream regulators of stemness that are amenable for targeting in PDAC is essential for the advancement of more potent therapeutic approaches. In this study, we sought to elucidate the function of the nuclear receptor subfamily 5, group A, member 2 (NR5A2) in the context of pancreatic CSCs.

Registos relacionados